These authors contributed equally: W. Vallen Graham and Weiqi He. *e-mail: jrturner@bwh.harvard.edu E pithelial barriers are essential for survival. Barrier dysfunction, which characterizes many diseases, can occur by two distinct mechanisms. The first, cellular damage, results in catastrophic barrier loss. A second, more nuanced mechanism reflects increased permeability of the tight junctions that seal the paracellular space 1 . This selectively permeable seal is regulated by MLCK and MLC phosphorylation within the PAMR 2, 3 . MLCK isoforms expressed in various epithelia and smooth muscle (visceral and vascular) are encoded by a single gene, MYLK, and have identical catalytic and calmodulin-binding regulatory domains (Fig. 1a ) 4, 5 . The approximately 210 kDa long MLCK expressed in epithelia includes additional 5′ exons that encode six amino-terminal immunoglobulin-like cell adhesion molecule (IgCAM) domains; these are absent in smooth muscle (short) MLCK (Fig. 1a ) 6 . Intestinal epithelia express two splice variants of long MLCK, MLCK1 and MLCK2 (Fig. 1a) , but do not express short MLCK 7 . These long MLCK variants differ by a single exon that is only present in MLCK1 and completes IgCAM3 7, 8 . Long MLCK-deficient mice are viable, develop normally 9 , and are protected from acute lipopolysaccharide-and ventilatorinduced lung injury, acute TNF-induced intestinal barrier loss and diarrhea, and chronic, immune-mediated colitis 2, 9, 10 . In contrast, short MLCK knockout mice die soon after birth 11 . Thus, although long MLCK could be an attractive therapeutic target, systemic toxicity associated with enzymatic MLCK inhibition limits the utility of this approach.
In this study, we report an alternative strategy for the therapeutic inhibition of long MLCK-dependent barrier loss. We show that MLCK1, but not MLCK2, is recruited to the PAMR in response to pathogenic stimuli. Using an in silico structure-based screen, we have identified a small molecule that binds to IgCAM3 and prevents stimulus-induced MLCK1 recruitment to the PAMR. This molecule, termed divertin because it diverts MLCK1 from the PAMR, does not interfere with MLCK enzymatic activity, epithelial cell wound repair, or smooth muscle contraction. However, it prevents MLCKmediated intestinal barrier loss in vitro and in vivo, restores barrier function in spontaneous colitis, and attenuates experimental, immune-mediated colitis. We conclude that IgCAM3-dependent MLCK1 recruitment to the PAMR is a viable target for therapeutic preservation of epithelial barrier function in intestinal disease and may also be beneficial in pathophysiologies affecting other organs.
with lateral membranes (Fig. 1c) . However, MLCK1-EGFP demonstrated significantly greater localization within the apical PAMR relative to MLCK2 ( Fig. 1d ; P < 0.05). Moreover, TNF, which activates MLCK-dependent phosphorylation of perijunctional MLC 2, 12 , markedly increased the PAMR-associated pool of MLCK1, but not MLCK2 ( Fig. 1c,d ; P < 0.01). Analysis of non-transfected Caco-2 BBe monolayers confirmed recruitment of endogenous MLCK1 that began within 0.5 h of TNF addition and continued to 4 h (Fig. 1e) . Notably, MLCK1 redistribution did not occur in the absence of interferon-γ (IFN-γ) pretreatment, which is necessary to induce TNF receptor expression in these monolayers 13 . Thus, endogenous MLCK1 and MLCK1-EGFP, but not MLCK2-EGFP, demonstrate TNF-induced MLCK1 recruitment to the PAMR in intestinal epithelial monolayers in vitro.
To determine if MLCK1 recruitment to the PAMR occurs in vivo, the intestines of immunodeficient mice with colitis induced by adoptive transfer of CD4 + CD45RB hi naïve effector T cells 14 were examined. In colonocytes from these mice, MLCK1 was mostly concentrated within the apical cytoplasm where it formed a distinct line at the level of the PAMR ( Fig. 1f ; lower panel, arrow). In contrast, MLCK1 was distributed diffusely within the colonocytes of healthy mice ( Fig. 1f ; upper panel). Thus, MLCK1 is recruited to the PAMR during chronic immune-mediated disease.
Identification and analysis of potential MLCK1 IgCAM3-targeted small molecules. The 69 amino acids encoded by exon 8, which complete IgCAM3, are the only difference between MLCK1 and MLCK2. Therefore, we hypothesized that a small molecule that binds to IgCAM3 might interfere with MLCK1 recruitment to the PAMR. To identify such a molecule, we solved the crystal structure of IgCAM3 to 2.5 Å (Fig. 2a and Supplementary Table 1) . Overall, IgCAM3 formed a Greek key β-sandwich that is characteristic of the IgCAM superfamily 15 . The overall structure was also similar to that reported for telokin, which forms the IgCAM9 of long and short MLCK 16 . Structural and sequence data from all IgCAMs of human and mouse MLCK1 were used to select a potential drug-binding pocket that: (1) was comprised of residues that are unique to IgCAM3 (Fig. 2a) ; (2) was conserved between mouse and human MLCK1 (Fig. 2b) ; and (3) had a suitable, surface-accessible, hydrophobic core (Extended Data Fig. 1a) . A library of approximately 140,000 molecules was docked in silico and the compounds with the lowest predicted binding energy were obtained for functional testing (Extended Data Fig. 1b) .
As an initial, medium-throughput biological screen, we assessed the ability of small molecules to reverse physiological, MLCKdependent tight junction permeability increases 17 . Activation of Na + -glucose cotransport reduced transepithelial electrical resistance (TER), a sensitive measure of paracellular permeability, in Caco-2 BBe monolayers (Fig. 2c) . A highly specific MLCK inhibitor, membrane permeant inhibitor of myosin light chain kinase (PIK) 18 , reversed the effects of Na + -glucose cotransport on barrier function. Small molecules with very low (left group) and intermediate (right group) predicted ΔG of binding to IgCAM3 were tested. Images are representative of more than 10 independent experiments. c, Caco-2 BBe monolayers expressing MLCK1-EGFP or MLCK2-EGFP were primed with IFN-γ followed by treatment with TNF for 4 h. Images are representative of more than 12 independent experiments. Bar, 10 μm. d, MLCK1-EGFP or MLCK2-EGFP colocalization with F-actin at the PAMR was determined. For this experiment, which is representative of 4 independent studies, n = 8 biologically independent samples with 3-5 fields analyzed for each condition. *P < 0.05; **P < 0.01 by Kruskal-Wallis test with Dunn's multiple comparison test. e, Monolayers were treated with IFN-γ and/or TNF, as indicated, before immunostaining for endogenous MLCK1 and F-actin. PAMR localization of endogenous MLCK1 was determined. The data show the fraction of total MLCK1 localized to the PAMR and are therefore independent of absolute MLCK1 expression, which increases in response to TNF. For this experiment, which is representative of 4 independent studies, n = 3 biologically independent samples with 3-4 fields analyzed for each condition. **P < 0.01 by ANOVA with Dunn's multiple comparison test. The mean ± s.e.m. is shown. f, Colon sections from healthy mice (control) or those with T cell transfer colitis (colitis) were stained for MLCK1 (green) and nuclei (blue). The intensity of MLCK1 staining in colonocytes from healthy control mice is enhanced to allow direct comparison with diseased colonocytes, which have increased MLCK1 expression. The arrows indicate the position of the PAMR, where a distinct line of MLCK1 can be detected in colonocytes from colitic, but not control, mice. Bar, 5 μm. Images representative of more than 6 independent experiments are shown.
Three molecules from the very low ΔG group, NSC31211, NSC159456, and NSC55937, but none from the intermediate ΔG group, increased the TER of monolayers with active Na + -glucose cotransport to an extent similar to PIK (Fig. 2c and Supplementary  Table 2 ). In addition to identifying three molecules that passed this screen, this result suggests that the ΔGs predicted by the in silico model are relevant in vitro.
Enzymatic MLCK inhibition could be a simple explanation for the effects of small molecules on TER. To evaluate this, the effects on intestinal epithelial MLCK activity were tested in a cellfree assay. Several small molecules, including one of the three that increased TER (NSC159456), inhibited MLCK activity (Fig. 2d and  Supplementary Table 2 ). Thus, of the small molecules that enhanced barrier function, only NSC31211 and NSC55937 passed this screen.
As inhibition of MLCK-dependent smooth muscle contraction, which is essential for normal gastrointestinal motility and regulation of vascular tone 19 , would represent an unacceptable toxicity, we assessed the effect of small molecules on the contraction of human smooth muscle cells. Consistent with the observed MLCK enzymatic inhibition, NSC42233 and NSC294786 limited contraction (Fig. 2e  and Supplementary Table 2 ). NSC31211 and NSC48770, which did not inhibit MLCK enzymatic activity, also reduced smooth muscledependent gel contraction. Therefore, NSC55937 was the only small molecule that increased TER without inhibiting MLCK enzymatic activity or smooth muscle contraction (Supplementary Table 2 ). Further, NSC55937 did not interfere with epithelial wound closure (Fig. 2f) , which requires intact MLCK function.
Consistent with our initial hypothesis that a small molecule bound to IgCAM3 might prevent MLCK1 recruitment, NSC55937 markedly reduced the PAMR-associated MLCK1 fraction (Fig. 2g) . In contrast, MLCK enzymatic inhibition did not affect MLCK1 localization. Because NSC55937 diverted MLCK1 from the PAMR, it was designated 'divertin' .
To directly measure divertin binding, we took advantage of the single tryptophan (W447) buried within IgCAM3 (Extended Data Fig. 2a PIK  294786  48770  68361  267461  122301  34629  Inactive  cotrasport  351093  42233  31211  14010  159456  353874  91855  55937  134514  641058 tryptophan fluorescence (Extended Data Fig. 2b ) and quenched overall fluorescence (Extended Data Fig. 2c ), consistent with movement of W447 to a more polar environment. Mutation of Leu449, Gln457, and Asp481, which line the putative drug-binding pocket, eliminated divertin-induced changes in tryptophan fluorescence (Extended Data Fig. 2d ). These data indicate that divertin binds specifically to MLCK1 IgCAM3 via an interaction at or near the putative drug-binding pocket.
Divertin reverses TNF-induced MLC phosphorylation and barrier loss in vitro. The data outlined in the previous section suggest that divertin-mediated inhibition of MLCK1 recruitment to the PAMR may reduce MLCK-dependent MLC phosphorylation and prevent or reverse TNF-induced tight junction barrier defects. Consistent with this hypothesis, divertin blocked TNF-induced MLCK1 recruitment to the PAMR (Fig. 3a,b) . Moreover, divertin restored barrier function in TNF-treated Caco-2 BBe monolayers in a manner that was similar to enzymatic MLCK inhibition (Fig. 3c) . The rapidity of this TER restoration strongly suggests that, consistent with previous work, the effect of divertin reflects regulation of paracellular, rather than transcellular, transport. Finally, divertin reversed TNF-induced MLC phosphorylation (Fig. 3d) . Thus, although cell-free assays showed that divertin is not a direct inhibitor of MLCK enzymatic activity, it is as effective as an enzymatic inhibitor in correcting TNF-induced MLC phosphorylation and restoring barrier function. Together, these data suggest that divertin acts by preventing MLCK1 from gaining the physical proximity required for phosphorylation of perijunctional MLC (Fig. 3e) .
Divertin prevents acute TNF-induced MLC phosphorylation, barrier loss, and diarrhea in vivo. The in silico screen was designed to identify small molecules capable of interacting with both human and mouse MLCK1 to allow the analysis of divertin efficacy in vivo. Mouse jejunal segments were perfused in situ as described previously ( Fig. 4a ) 2, 20 . Intraperitoneal TNF administration reversed the direction of fluid flow to net secretion (Fig. 4b) , induced barrier loss (Fig. 4c) , and enhanced intestinal epithelial MLC phosphorylation (Fig. 4d) . The addition of divertin to the perfusate in a manner topologically analogous to oral administration restored fluid absorption, prevented barrier loss, and blocked TNF-induced increases in MLC phosphorylation. Divertin did not interfere with basal fluid transport or barrier function in the absence of TNF, suggesting that it is unlikely to negatively impact epithelial homeostasis or intestinal transport under basal conditions. Divertin prevented TNF-induced recruitment of MLCK1 to the PAMR (Fig. 4e,f) , although it did not interfere with TNF-induced upregulation of MLCK1 expression 21 . Divertin also prevented TNFinduced phosphorylation of perijunctional MLC (Fig. 4g) . Previous work has shown that caveolar endocytosis of the tight junction protein occludin is both required for and is a robust marker of TNF-induced MLC phosphorylation-mediated barrier regulation 20 . Consistent with this, divertin prevented TNF-induced occludin endocytosis (Fig. 4h) 
20
. These data indicate that divertin-mediated disruption of MLCK1 recruitment can prevent TNF-induced tight junction barrier loss and diarrhea in vivo.
Divertin prevents TNF-induced MLCK1 trafficking, MLC phosphorylation, and tight junction reorganization in human jejunal mucosae ex vivo. To determine if divertin is also effective in the human jejunum, mucosal biopsies from normal human individuals were treated with TNF and divertin ( Fig. 4i) . As in intact mouse jejunum, divertin prevented TNF-induced MLCK1 recruitment to the PAMR in human jejunal enterocytes (Fig. 4j,k) . However, divertin did not interfere with TNF-induced upregulation of MLCK1 expression (Fig. 4k) , indicating that divertin did not simply block TNF signaling within intestinal epithelia. Divertin also limited TNF-induced perijunctional MLC phosphorylation (Fig. 4l) . Although barrier function was not measured directly, the ability of divertin to inhibit the endocytosis of tight junction-associated For this experiment, which is representative of 5 independent studies, n = 8 biologically independent samples with 3-5 fields analyzed for each condition. The mean ± s.d. is shown. *P < 0.05; **P < 0.01 by ANOVA with Dunn's multiple comparison test. c, TER of IFN-γ-primed monolayers treated with TNF for the indicated times. After 3 h (arrow), vehicle, 150 μM PIK, or 150 μM divertin was added to the apical media. For this experiment, which is representative of 3 independent studies, n = 3 biologically independent samples for each condition. The mean ± s.d. is shown. **P < 0.01 by repeated-measures ANOVA with Bonferroni correction. d, Immunoblots of phosphorylated MLC (pMLC) and actin from monolayers treated with IFN-γ for 16 h and TNF for 4 h; 150 µM PIK or 150 µM divertin were added at 3 h. For this experiment, which is representative of 3 independent studies, n = 3 biologically independent samples for each condition. The mean ± s.d. is shown. **P < 0.01 by ANOVA with Dunn's multiple comparison test. e, Proposed mechanism of divertin action.
occludin (Fig. 4m) is strong evidence that TNF-induced barrier loss was prevented or reversed 20 . Thus, similar to intact mouse jejunum, divertin prevents TNF-induced MLCK1 trafficking, MLC phosphorylation, and occludin endocytosis in human jejunal epithelia.
Divertin does not have significant toxicity. These analyses, where intestinal epithelial cells were directly exposed to divertin, show that this small molecule protects human and mouse cells and tissues from acute TNF-induced MLCK1 trafficking, MLC phosphorylation, occludin endocytosis, and barrier dysfunction in vitro, in vivo, and ex vivo. To determine whether divertin could be therapeutically effective in chronic disease, we first assessed the potential toxicity of systemic administration. A previous analysis in leukemia showed that daily intraperitoneal injections of 50 mg kg −1 or 100 mg kg −1 , for nine or three days, respectively, had no effect on survival after 30 d 22 . Consistent with this, we found that daily intraperitoneal injections of 12.5 mg kg −1 or 25 mg kg −1 were without toxicity, in terms of weight loss or behavior, over 31 d (Fig. 5a ). Daily 50 mg kg −1 doses did not affect survival or behavior but induced weight loss (data not shown).
To better characterize potential toxicity, histopathology and epithelial turnover were assessed in the small intestine and colon after divertin treatment. No divertin-induced histopathology was evident on hematoxylin and eosin (H&E)-stained sections. Moreover, divertin had no effect on epithelial turnover; the numbers of 5-ethynyl-2′-deoxyuridine (EdU)-labeled cells were similar in the small intestine and colon ( Fig. 5b ) of mice treated with 12.5 mg kg day −1 or 25 mg kg day −1 of divertin for 31 d. Thus, divertin does not appear to have systemic, mucosal, or epithelial toxicity over this relatively short period of exposure.
Divertin limits the development of experimental inflammatory bowel disease (IBD).
These data indicate that divertin can prevent acute inflammatory diarrhea when given before disease onset and is not toxic when given daily at a dose of 25 mg kg
. To determine if divertin can also prevent the initiation and subsequent progression of chronic disease, we used a T cell transfer model. We have previously reported that intestinal epithelial MLCK activation accelerates disease progression and, conversely, intestinal epithelial MLCK knockout delays onset and lessens disease severity in this IBD model 10, 23 . Mice were treated with daily intraperitoneal injections of divertin or saline (vehicle) beginning 14 d after adoptive transfer, before the onset of symptoms (Extended Data Fig. 3a ). Mice treated with saline developed disease activity and began to lose weight one week later (day 21), but this was delayed by nearly two weeks, to day 33, in mice that received divertin (Extended Data Fig. 3a,b) . Divertin also prevented mortality in this colitis model (Extended Data Fig. 3c ).
As expected, disease progression in saline-treated mice was associated with increased intestinal permeability to 4 kDa dextran (28 Å diameter), but barrier function was largely preserved in divertintreated mice (Extended Data Fig. 3d ). Consistent with reduced disease, mucosal TNF production was also lower in divertin-treated mice (Extended Data Fig. 3e ). Finally, the efficacy of divertin in preventing disease development was evident on gross examination as reduced colonic shortening and thickening (Extended Data Fig. 3f ) and on microscopic examination by reduced inflammation and mucosal hyperplasia (Extended Data Fig. 3g,h ). Therefore, divertin can limit the initial development of experimental IBD.
Divertin acutely restores barrier function in spontaneous immune-mediated colitis. We used the interleukin-10 (IL-10) knockout mouse model of spontaneous colitis to determine whether divertin could restore intestinal barrier function in chronic disease 24, 25 . Intestinal permeability was assessed in IL-10 knockout mice with mild disease and reassessed one week later in the same mice following a single 25 mg kg −1 dose of divertin. Intestinal permeability to fluorescein, a sensitive marker of tight junction barrier loss due to its small size (hydrodynamic diameter = 8 Å), in IL-10 knockout mice was 2.9 ± 0.3-fold that of wildtype controls, consistent with the presence of disease (Fig. 5c) . The recognized variability of disease severity in IL-10 knockout mice is reflected in the significantly greater range of intestinal permeability of IL-10 knockout mice relative to wild-type controls (Fig. 5c) . Divertin collapsed the range of permeabilities and reduced the absolute fluorescein permeabilities in IL-10 knockout mice such that they were similar to wild-type mice (Fig. 5c) . Overall, divertin reduced intestinal permeability in 9 of 11 IL-10 knockout mice . b, TNF induces net fluid secretion, but divertin restores absorption. n = 4 biologically independent samples for each condition. The mean ± s.d. is shown. **P < 0.01 by ANOVA with Dunn's multiple comparison test. c, TNF-induced increases in albumin leak from the bloodstream to the gut lumen are blocked by divertin. n = 4 biologically independent samples for each condition. The mean ± s.d. is shown. **P < 0.01 by ANOVA with Dunn's multiple comparison test. d, Divertin blocks TNFinduced MLC phosphorylation. n = 3 biologically independent samples for each condition in this experiment, which is representative of 3 independent experiments. The mean ± s.d. is shown. **P < 0.01 by ANOVA with Dunn's multiple comparison test. e, Divertin blocks acute, TNF-induced MLCK1 recruitment to the PAMR. n = 2 fields in each of 3 independent mice for each condition in this experiment, which is representative of 3 independent experiments. The mean ± s.d. is shown. **P < 0.01 by ANOVA with Dunn's multiple comparison test. f, Micrographs showing that divertin blocks TNF-induced MLCK1 (green) recruitment to the PAMR. F-actin (red), nuclei (blue). Images are representative of 9 independent mice (3 in each of 3 experiments) per condition. Bar, 10 μm. The line scans show the intensity of the staining from the apical to the basal part of the cell. Arrows in the line scan graphs indicate colocalization of MLCK1 with the PAMR in TNF-treated mice. n = 2 fields in each of 3 independent mice for each condition in this experiment, which is representative of 3 independent experiments. The mean ± s.d. is shown. g, Divertin blocks TNF-induced increases in MLC phosphorylation (green) within the PAMR. F-actin (red), nuclei (blue). Bar, 10 μm. Images are representative of 9 independent mice (3 in each of 3 experiments) per condition. h, Divertin blocks TNF-induced internalization of occludin (green). F-actin (red), nuclei (blue). Bar, 10 μm. Images are representative of 9 independent mice (3 in each of 3 experiments) per condition. i, Human jejunal mucosal biopsies were incubated ex vivo with TNF and/ or divertin. j, Divertin blocks TNF-induced MLCK1 recruitment to the PAMR but does not block TNF-induced increases in MLCK1 expression. n = 2 fields in each of 3 biologically independent specimens for each condition in this experiment, which is representative of 3 independent experiments. The mean ± s.d. is shown. ***P < 0.001 by ANOVA with Dunn's multiple comparison test. k, Divertin blocks TNF-induced MLCK1 (green) recruitment to the PAMR. F-actin (red), nuclei (blue). Bar, 10 μm. Images are representative of 9 biologically independent specimens (3 in each of 3 experiments) per condition. The line scans show the intensity of the staining from the apical to the basal part of the cell. n = 2 fields in each of 3 biologically independent specimens for each condition in this experiment, which is representative of 3 independent experiments. l, Divertin prevents TNF-induced phosphorylation of PAMR-associated MLC (green). F-actin (red), and nuclei (blue). Bar, 10 μm. Images are representative of 9 biologically independent specimens (3 in each of 3 experiments) per condition. m, Divertin blocks TNF-induced occludin internalization (green). F-actin (red), nuclei (blue). Bar, 10 μm. Images are representative of 9 biologically independent specimens (3 in each of 3 experiments) per condition.
but only 4 of 8 wild-type mice (Fig. 5c ). These data indicate that divertin can restore intestinal barrier function in a mechanistically relevant IBD model.
Divertin limits the severity of experimental chronic IBD.
The disease variability inherent in IL-10 knockout mice makes it difficult to use this model to test the efficacy of divertin as therapy for established disease. Therefore, we returned to the T cell transfer model (Fig. 6a) , where disease is relatively uniform in each mouse. Like human disease, this model is responsive to anti-TNF therapy 14 . By day 18 after transfer, all mice that had received T cells displayed softened stool, weight loss, and modest increases in clinical scores. These mice were randomized into four treatment groups. Separate groups of mice received saline or divertin beginning on day 19 after T cell transfer. These were compared to mice treated with anti-TNF antibodies, which are effective in T cell transfer colitis 14 . We also asked if combination therapy with divertin and anti-TNF provided any benefit relative to each agent alone.
Divertin, anti-TNF, and the combination of divertin and anti-TNF each limited weight loss over the first week of treatment (Fig. 6b) . Thereafter, weight loss accelerated in anti-TNF-treated mice; by day 35, the weights of mice receiving anti-TNF or vehicle (saline) were comparable (Fig. 6b) . While all three drug treatments also significantly limited disease activity, the combination treatment was better than either drug alone (Fig. 6c) . This trend was mirrored by survival, since combination treatment was the only intervention that resulted in 100% survival at day 35. Divertin, but not anti-TNF, treatment also significantly improved survival relative to mice that received only saline (Fig. 6d) .
Similar to survival, divertin or combination treatment, but not anti-TNF alone, significantly prevented colonic shortening and thickening (Fig. 6e) . Nevertheless, all three treatments resulted in significant preservation of intestinal barrier function as assessed by 4 kDa dextran (28 Å diameter) permeability (Fig. 6f) . Thus, most analyses showed divertin to be modestly more effective than anti-TNF. Combination treatment was superior to either drug alone in preventing progression of clinically evident disease activity; by all other measures, addition of anti-TNF provided no benefit relative to divertin alone. In a manner that correlated directly with survival, colonic mucosal T cell infiltration in mice treated with saline or anti-TNF was markedly greater than that in mice that received divertin alone or combination treatment (Fig. 6g) .
Both divertin and anti-TNF treatments significantly reduced fecal water content, that is, diarrhea (Fig. 6h) , but the effect of divertin was not significantly different than that of anti-TNF. Consistent with this, colonic TNF, IFN-γ, IL-1β, and keratinocyte chemoattractant (IL-8) production were significantly reduced in divertin-treated, relative to saline-treated, mice. Anti-TNF treatment, in contrast, reduced only IL-1β and keratinocyte chemoattractant (Fig. 6i) . Divertin was also more effective than anti-TNF in limiting histopathological features of disease (Fig. 6j) . Crypt loss (asterisks), crypt abscesses (arrows), goblet cell (mucin) depletion, dense lamina propria lymphoplasmacytic infiltrates, and mucosal hyperplasia were not substantially affected by anti-TNF treatment (Fig. 6k) . Crypt abscesses were uncommon in divertin-treated mice and mucin-laden goblet cells (arrowheads) were preserved. Moreover, although some crypt elongation was present in divertintreated mice, overall mucosal hyperplasia was substantially reduced relative to saline-and anti-TNF-treated mice (Fig. 6j,k) . Thus, consistent with attenuation of weight loss, colonic shortening, and TNF and IFN-γ production, divertin, but not anti-TNF, significantly reduced the histopathological features of colitis. Overall, these data indicate that divertin can both reduce severity and limit progression of experimental IBD.
Discussion
Epithelial barrier loss is a critical component of acute and chronic gastrointestinal diseases, including infectious enterocolitis, food allergy, celiac disease, and IBD 26 . This relationship is further emphasized by the observations that intestinal epithelial barrier loss in healthy individuals is linked to IBD risk alleles [27] [28] [29] and that barrier loss during remission is a prognostic marker of disease reactivation in Crohn's disease 30 . Experimental models further show that intestinal epithelial barrier dysfunction precedes the onset of enterocolitis 31 , that increased intestinal permeability enhances IBD progression 23, 32 , and that barrier restoration limits IBD pathogenesis 23, 31 . Although the molecular mechanisms that trigger intestinal permeability defects are incompletely defined, non-muscle MLCK activation is a convergence point for many pathophysiological stimuli. MLCK is also implicated in barrier dysfunction in other organ systems and in vascular endothelia; therefore, it represents a potential . Body weight changes, normalized to initial body weight, are shown. For this experiment, which is representative of 3 independent studies, n = 5 biologically independent samples for each condition. The mean ± s.d. is shown. b, Mice were injected with EdU (green) 16 h before being killed. E-cadherin (red) is shown for orientation. Each point represents the mean of five microscopic fields from a single mouse. The mean ± s.d. is shown. n = 4 mice per condition in this representative experiment. No groups were significantly different from any other group (ANOVA with Dunn's multiple comparison test). c, Wild-type or IL-10 knockout mice were gavaged with fluorescein and injected intraperitoneally with vehicle. Serum fluorescein recovery at 3 h was used as a measure of intestinal permeability. The same mice were injected intraperitoneally with a single 25 mg kg −1 dose of divertin and gavaged with fluorescein one week later. The lines connect data from individual mice without (green) or with (red) divertin treatment. The data are normalized to the mean of healthy wild-type mice. n = 8 (wild-type), n = 11 (IL-10 knockout). **P < 0.01 by two-sided paired t-test. therapeutic target. However, the catalytic domains of non-muscle and smooth muscle MLCK are identical; thus enzymatic inhibitors that target one will target both. This would be a source of substantial toxicity, since smooth muscle MLCK inhibition results in hypotension, intestinal obstruction, and death 19 . Further, the most widely used non-muscle and smooth muscle MLCK inhibitors, ML-7 and ML-9, inhibit many other kinases, including cardiac and skeletal muscle MLCK, rho-associated protein kinase 2, 5′ AMP-activated protein kinase, and dual specificity tyrosine-phosphorylation-regulated kinase 1, at concentrations that fail to inhibit smooth and non-muscle MLCK completely 33 . Together with recognition that MLCK serves critical roles in epithelial migration and wound repair, among other functions, enzymatic MLCK inhibition is unlikely to be achievable without toxicity.
In the current study, we demonstrate an alternative therapeutic strategy for preventing MLCK-dependent barrier dysregulation in acute and chronic intestinal disease. We show that a specific long MLCK splice variant, MLCK1, is recruited to the PAMR where it mediates TNF-induced intestinal epithelial tight junction regulation. Taking advantage of the unique IgCAM3 within MLCK1, we screened for compounds that bind to this domain. Secondary screens identified molecules that could enhance barrier function and eliminated those that inhibited MLCK enzymatic activity or smooth muscle contraction. One small molecule, termed divertin, binds to this unique IgCAM domain and prevents MLCK1 recruitment to the PAMR without interfering with epithelial migration and wound repair.
To assess the effects of divertin in intact tissue, we used an established in vivo mouse model of TNF-induced, MLCK-dependent diarrhea 2, 20, 34 and acute TNF-induced MLCK activation leading to tight junction reorganization in human jejunal mucosae ex vivo. In both tissues, divertin prevented MLCK1 recruitment to the PAMR and subsequent phosphorylation of perijunctional MLC. Further, divertin prevented TNF-induced diarrhea and restored net fluid absorption in mouse jejunum in vivo. This functional preservation correlated directly with maintenance of occludin at the tight junction pools, that is, inhibition of endocytosis. These data confirm the necessity of depleting occludin from the tight junction to drive TNFinduced barrier loss and diarrhea; previous studies have shown that occludin overexpression, which augments tight junction occludin pools, or direct, genetic, or pharmacological inhibition of occludin endocytosis limits TNF-induced barrier loss and diarrhea in mice 20 . Thus, while we were unable to measure transport, the efficacy of divertin in blocking occludin endocytosis in human intestinal biopsies can be taken as de facto evidence that paracellular barrier function and transepithelial fluid transport were preserved. Thus, divertin is equally effective in an in vivo mouse model and an ex vivo human model of acute, TNF-induced tight junction barrier loss. Moreover, these data indicate that divertin has no effect on epithelial morphology, tight junction structure, barrier function, or fluid transport in the absence of stimuli but can prevent the development of TNF-induced barrier loss. Finally, when given before clinical presentation, divertin limited experimental IBD development. These data indicate that divertin might be safely used prophylactically, for example, as a maintenance therapy in IBD.
In vitro, divertin reversed both the morphological and functional sequelae of acute TNF-induced MLCK activation, including perijunctional MLC phosphorylation, tight junction reorganization, and barrier loss. Divertin had a similar effect in vivo, where a single dose restored intestinal barrier function in colitic IL-10 knockout mice. These data suggest that continuous divertin treatment might be effective in established disease. To assess this, mice received T cell transfer, but therapy was not initiated until day 19, after weight loss, disease activity, cytokine production, and histopathological features of experimental IBD were established. In this model, divertin was compared directly to treatment with anti-TNF antibodies, which have revolutionized therapy in human IBD. Consistent with previous work 14 , anti-TNF treatment provided only partial protection from T cell transfer, colitis-associated weight loss and mortality. In contrast, divertin limited weight loss and mortality. Thus, by these measures, divertin was superior to anti-TNF treatment. Because they have different mechanisms of action, we hypothesized that divertin and anti-TNF treatment might have additive effects. However, combination therapy was not significantly superior to divertin alone by any measure.
The efficacy with which divertin prevents barrier loss and restores function suggests that it may also be useful in other diseases with epithelial and vascular endothelial tight junctions dysfunction, including celiac disease 29, 35 , atopic dermatitis 36 , pulmonary infection and acute respiratory distress syndrome 37, 38 , graft versus host disease 39 , and multiple sclerosis 40, 41 . Moreover, the molecularly targeted approach defined in this study may have much broader relevance since recruitment to specific subcellular locations is essential for the function of proteins involved in diverse cellular activities including mitosis, membrane trafficking, cytoskeletal regulation, and ion transport [42] [43] [44] . Disruption of site-specific recruitment may allow + effector T cells. Therapy by daily intraperitoneal injection with saline (vehicle), divertin, anti-TNF, or combined divertin and anti-TNF was initiated after definitive features of disease were present (day 19). b-g, Female mice were used in this experiment, which included n = 7 mice without T cell transfer and n = 8 mice in each of the other 4 groups. b,c, Normalized weight data and disease activity scores. The mean ± s.d. is shown. **P < 0.01 by two-tailed t-test for no transfer versus all other mice at day 18. ***P < 0.001 by ANOVA with Tukey's multiple comparison test over the interval from 19 to 35 d. d, Survival. *P < 0.05, versus saline-treated mice, by Gehan-Breslow-Wilcoxon test. e,f, Colon length. The mean ± s.d. is shown. *P < 0.05; **P < 0.01, versus saline-treated mice, by ANOVA with Newman-Keuls multiple comparison test. f, Intestinal permeability to FITC-4 kDa dextran. Data are normalized to mice that did not receive T cell transfer. The mean ± s.d. is shown. *P < 0.05, versus saline-treated mice, by ANOVA with Newman-Keuls multiple comparison test. g, Colonic mucosa immunostained for CD3 (green) and E-cadherin (red). Bar, 50 μm. Images are representative of two independent experiments. h-k, Male mice were used in this experiment, which included n = 10 saline-treated mice and n = 7 mice in each of the other groups. Weight loss, disease activity, and survival were similar to the experiment using female mice (b-g). h, Fecal water content of male mice after T cell transfer (from male donors; fecal water was 53 ± 4% for mice that did not receive T cell transfer and 66 ± 8% at day 18 for mice that received T cells). The mean ± s.d. is shown. **P < 0.01; ***P < 0.001 by ANOVA with Bonferroni correction. i, The indicated cytokines were determined by ELISA in distal colonic homogenates. The mean ± s.d. is shown. n = 8 for saline-treated mice (n = 7 for IFN-γ and IL-1β); n = 7 for divertin-treated mice; n = 4 for anti-TNF-treated mice. *P < 0.05; **P < 0.01; ***P < 0.001 by ANOVA with Bonferroni correction. The mean cytokine levels of mice that did not receive T cell transfer or were killed 18 d after transfer were, respectively: TNF 11 pg mg −1 and 37 pg mg ; IL-1β undetectable and 58 pg mg certain processes to be blocked without affecting other essential functions. Therefore, our characterization of divertin demonstrates a novel means of enhancing therapeutic specificity without many of the toxicities that often plague less precisely targeted inhibitors.
In summary, we have shown that the long MLCK splice variant MLCK1 is recruited to the intestinal epithelial tight junction in response to inflammatory stimuli. We used a structure-based drug discovery approach to identify a small molecule that blocks MLCK1 recruitment, corrects acute inflammatory barrier loss and diarrhea, and prevents chronic immune-mediated colitis. In addition to the potential of this specific agent, this approach to kinase inhibition by limiting substrate accessibility, rather than enzymatic activity, 
Methods
Cloning and vector construction. The human MLCK1 IgCAM3 domain sequence was selected based on the previously solved structure of IgCAM9, also known as telokin (Protein Data Bank code: 1tlk) 16 . Oligonucleotides were designed based on the human MLCK1 complementary DNA (cDNA) sequence (GenBank accession no. AY424270): forward, 5′-ATGGAGGGCCA GAGGGATTCA-3′; reverse, 5′-CTATTCCACTT GGAGGGTCCA GCTACAG-3′. These primers correspond to nucleotides 1215-1517 of the cDNA sequence. In addition to the native MLCK1 cDNA sequence, the reverse primer included an artificial stop codon (in antisense) at its 5′ end. The final peptide encoded by the PCR amplicon represents the entire IgCAM3 domain of MLCK1, that is, amino acids 405-506 of the complete protein (GenBank accession no. AAR29062). The PCR products were ligated into pETBlue-1 (EMD Millipore) and sequenced for confirmation. Amino acid substitution to create mutant IgCAM3 (IgCAM3 Leu449Arg, Gln457Lys, Asp481Val) was done by mutagenesis using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). Oligonucleotides were: Leu449Arg sense 5′-TGAAGTGGCCTG GTTCAGAGA AGGCACCCCC GTGA-3′; Leu449Arg antisense 5′-TCACGG GGGTGCCTT CTCTGAACCA GGCCACTTCA-3′; Gln457Lys sense 5′-CCCCCGT GAGGAGAAAG GAAGGCAGCA TTG-3′; Gln457Lys antisense 5′-CAATGC TGCCTTCC TTTCTCCTCAC GGGGG-3′; Asp481Val sense 5′-GAAAG CCCGGACCA GGGTAAGTG GGACATA CAGCTG-3′; Asp481Val antisense 5′-CAGCTGT ATGTCCCACTT ACCCTGGTCCG GGCTTTC-3′. MLCK1-EGFP and MLCK2-EGFP fusion protein constructs were generated using MLCK1 (AY424270.1) and MLCK2 (AY424269.1) cDNA cloned from Caco-2 BBe and fused at the C terminus to monomeric EGFP (after removing the stop codon). These were cloned into piggyBAC-TREtight plasmids and stably expressed in Caco-2 BBe cells, as described 45 . All constructs were verified by direct sequencing.
Recombinant protein expression and purification. Constructs were transformed into BL21-CodonPlus (DE3)-RIPL Competent Escherichia coli (Stratagene) cells for isopropyl β-d-1-thiogalactopyranoside (IPTG)-induced expression. Cultures were grown to an A 600 of 0.5-0.9 at 37 °C and IPTG was added to a final concentration of 1 mM. Cultures were grown for an additional 3 h at 37 °C. After induction, bacteria were collected by centrifugation (6,000g), lysed (50 mM Tris, pH 7.5, 150 mM NaCl, 0.05% NP-40) and sonicated. SDS-PAGE confirmed expression. Solubilized protein was initially passed through a series of centrifugal filtration devices (Amicon) to concentrate proteins in the 3-30 kDa size range. These preparations were further purified through a Bio-Gel P-30 (Bio-Rad Laboratories) size-exclusion column (1.5 × 50 cm 2 ) chromatography using a BioLogic LP Chromatography System (BioRad Laboratories). The Bio-Gel column was equilibrated with 10 mM Tris, pH 8.0, 50 mM NaCl and the protein sample was fractionated at a rate of 1 ml min −1 . SDS-PAGE confirmed the positive fractions and these fractions were pooled and concentrated to 2 mg ml −1 with a purity of > 95% using centrifugal filtration.
Crystallization and data collection. The purified MLCK1 IgCAM3 domain was concentrated to 6 mg ml −1
. Crystals of the MLCK1 IgCAM3 domain were obtained from the NeXtal PEGs screen (Qiagen) condition H7 (200 mM ammonium dihydrogen phosphate, 20% PEG3350) at 4 °C. Crystals were mounted in a nylon loop and frozen in liquid nitrogen. Data were collected at the Advanced Light Source, beamline 5.0.2, wavelength 1.0 Å, at 100 K. The X-ray structure was determined by molecular replacement using MrBump 46 as implemented in the CCP4 version 7.0.048 program suite 47 . Refinement and model building were performed with BUSTER version 2.11.7 48 and Coot version 0.8.8 49 , respectively, using data to 2.5 Å, with 98.2% in preferred and allowed regions of the Ramachandran plot. Data collection and refinement statistics appear in Supplementary Table 1.
Molecular docking and acquisition of potential IgCAM3 interacting molecules.
The NCI Developmental Therapeutics Program chemical library was filtered for compounds that met the Lipinski's rule of five. The three-dimensional coordinates for the NCI/Developmental Therapeutics Program set of 139,735 plated compounds was obtained from ZINC 50 . All docking calculations were performed with DOCK 6 (University of California, San Francisco) and run by parallel processing on 16 central processing units of a Linux cluster at the University of Florida's High Performance Computing Center. The general features of DOCK include rigid orienting of ligands to receptor spheres, AMBER energy scoring, generalized Born/surface area solvation scoring, contact scoring, internal nonbonded energy scoring, ligand flexibility, and both rigid and torsional simplex minimization. To prepare the site for docking, all water molecules were removed. Protonation of receptor residues was performed with DockPrep in Chimera 1.12 (University of California, San Francisco). The structure was explored using sets of spheres to describe potential binding pockets using SPHGEN_CPP. The number of orientations per molecule was 100. Intermolecular AMBER energy scoring (van der Waals + columbic), contact scoring, and bump filtering were implemented in DOCK 6. Chimera was used to generate the molecular graphic images. Top scoring non-proprietary compounds and designated compounds were obtained from the Developmental Therapeutics Program, National Cancer Institute, National Institutes of Health. Each compound was solubilized in dimethylsulfoxide at 10 mM and stored at −20 °C. Divertin synthesis. An aqueous formalin solution (0.2 mol, 37% w/v) was added dropwise to hydrazine (0.75 equivalent fractional volume, 0.15 mol) at 0 °C. Stirring was continued for 20 min at room temperature; then, the reaction mixture was left to stand at room temperature for 3 d. The crude product was filtered and washed with hot propan-2-ol to yield the product, octahydro(1,2,4,5)tetrazino(1,2-a) (1,2,4,5)tetrazine, as a white powder. The yield was 18%. The carbon, hydrogen and nitrogen elemental analysis yielded the following: C 32.70%; H 8.28%; N 56.60%. The proton ( 1 H) nuclear magnetic resonance (500 MHz, deuterium oxide) was 3.61 (d, J = 11.5 Hz, 2 H) and 3.32 (d, J = 11.5 Hz, 2 H).
Epithelial cell culture and TER measurement. Caco-2 BBe cells were grown as monolayers on collagen-coated polycarbonate membrane Transwell permeable supports (Corning) and used 17-20 d after confluence, as described previously 17 . Electrophysiological measurements were made using agar bridges and Ag/AgCl calomel electrodes. A 50-μA current was passed across the monolayers using a model 558 voltage clamp (University of Iowa Biomedical Engineering) to measure potential differences before and during the application of a 50-μA current. The transepithelial short-circuit current (I sc ) and TER were calculated with Ohm's law, as described 17 . For the drug screens (Fig. 2c) , it was not possible to test all drugs in a single experiment. All trials included monolayers with active Na + -glucose cotransport (where MLCK is active) 17, 51 and inhibited Na + -glucose cotransport, which blocks MLCK activation and typically produces an approximately 20% increase in TER 17, 52 . After measuring TER, small molecules (250 μM) were added to the apical surface (in the presence of active Na + -glucose cotransport) and the TER was measured after 60 min. The TER values for each monolayer after drug treatment were normalized to those before the drug was added. To control for differences in monolayer responsivity between experiments, a scale was developed using monolayers with active Na + -glucose cotransport (set to 0%) and inhibited Na + -glucose cotransport (set to 100%) for two-point calibration. The enzymatic MLCK inhibitor PIK, which increases TER similarly to inhibition of Na + -glucose cotransport at the 150 μM dose used, was included in each experiment. The scaled values shown for active and inhibited Na + -glucose cotransport, PIK treatment, and drug treatments are taken from multiple experiments.
For experiments examining cytokine-treated monolayers (Fig. 3c) , IFN-γ (10 ng ml
; PeproTech) was added to the basal chamber 16 h before TNF addition to induce TNF receptor expression 13 . Preliminary experiments showed that this did not affect TER. TER was then measured and TNF (1 or 2.5 ng ml ; PeproTech) was added to the basal chamber (at t = 0) without manipulating the apical media, as described 13, 53 . Drugs were added to the apical chamber only. The TER of each monolayer was normalized, at each time point, to the starting TER (before TNF addition) of that monolayer.
Tryptophan fluorescence. N-acetyl-L-tryptophanamide (NATA), recombinant IgCAM3, or mutant IgCAM3 were added to the phosphate buffer (10 mM potassium phosphate, pH 6.7, 130 mM NaCl) in a quartz cuvette. Samples were then analyzed on a FluoroMax-3 scanning fluorimeter (Horiba) at 25 °C using an excitation wavelength of 296 nm (1-nm bandwidth) and recording the emission spectra from 315 to 400 nm.
Animals.
All experiments were performed in an Association of Assessment and Accreditation of Laboratory Animal Care-accredited facility under protocols approved by the University of Chicago, Brigham and Women's Hospital, Boston Children's Hospital, and Soochow University Animal Care and Use Committees. All studies are in compliance with all relevant ethical regulations. For the acute studies, 7-10-week-old C57BL/6 mice (The Jackson Laboratory) received intraperitoneal injections of vehicle or 5 μg recombinant mouse TNF as described previously 20 . In vivo perfusion analyses were performed as described previously 2, 20 . Sections of jejunum were collected and snap-frozen in optimal cutting temperature media.
129S1/SvImJ and 129(B6)-Il10 tm1Cgn /J mice (The Jackson Laboratory) were used as controls and IL-10 knockouts, respectively, at 7-10 weeks of age. Mice received intraperitoneal injections of vehicle or divertin (25 mg kg divertin each day or 150 μg rat anti-mouse TNF clone XT3.11 (catalog no. BP0058, Bio X Cell) every 3 d. Mice receiving only anti-TNF received saline on the other days. For mice receiving combination treatment, divertin and anti-TNF were combined in a single intraperitoneal injection on days when both were given. Cytokines were measured in homogenates of distal colon by multiplex enzymelinked immunosorbent assay (Quansys Biosciences). Histopathology was scored on well-oriented colonic cross sections stained by H&E and scored semiquantitatively from 0 to 3 each for lymphoid infiltrates, polymorphonuclear infiltrates, mucosal hyperplasia, and ulceration (total 0-12), as described 10 .
Human tissue. Mucosa was removed from normal small intestine tissue excised during bariatric surgery and incubated in Hank's Balanced Salt Solution with 300 ng ml −1 recombinant human TNF, divertin (250 μM), or both, as indicated, for 60 min. Tissue was then snap-frozen in optimal cutting temperature media. De-identified, discarded human tissues were used under an exempted protocol that did not require informed consent. All procedures involving human tissues were approved by the University of Chicago institutional review board; all relevant ethical regulations were followed.
Immunoblotting. Lysates of Caco-2 BBe monolayers or jejunal epithelial cells, isolated as described previously 2 , were separated by SDS-PAGE (Bio-Rad Laboratories), transferred to polyvinylidene difluoride membranes, and blotted using affinity-purified rabbit anti-pMLC (Ser19) antibody (catalog no. 3671, Cell Signaling Technology) and a monoclonal mouse anti-β-actin clone AC-15 (catalog no. A-1978, Sigma-Aldrich) followed by peroxidase-conjugated secondary antibodies (Cell Signaling Technology) and enhanced chemiluminescent detection. Signal intensity was assessed using ImageJ (NIH).
Immunostaining. Caco-2 BBe monolayers grown on 5 cm 2 Transwell permeable supports were fixed in 2% paraformaldehyde and immunostained as described previously. Snap-frozen tissues were stored at −80 °C, after which 5 µm frozen sections were cut and fixed in 1% paraformaldehyde. EdU was detected using the Click-iT RNA Alexa Fluor 488 Imaging Kit (Invitrogen). Immunostaining used affinity-purified rabbit anti-human MLCK1 antibody (2 μg ml Microscopy. Specimens were imaged using an epifluorescence microscope (DM4000; Leica) equipped with 4,6-diamidino-2-phenylindole, Endow GFP, and Texas red zero-pixel shift filter sets (Chroma Technology), a 63 × 1.32 numerical aperture oil immersion objective, and a camera (CoolSNAP HQ; Roper Scientific) controlled by MetaMorph version 7. Z stacks were collected at 0.2 µm intervals and deconvolved using AutoDeblur version X1 (Media Cybernetics) for 10 iterations. Line scans (100 pixels wide) were performed using MetaMorph version 7. For formalin-fixed, paraffin-embedded specimens stained as part of tissues microarrays, tiled images were collected on a DM4000 microscope equipped with a Chroma filter sets (as detailed earlier), a 20 × HC PLAN APO numerical aperture 0.7 objective, CoolSNAP HQ2 grayscale charge-coupled device (CCD) (for fluorescence) and Jenoptik ProgRes C10 Plus color CCD (for transmitted light) cameras, and a motorized XYZ stage (Ludl) controlled with custom MetaMorph version 7 journals. Images were stitched using MetaMorph version 7. Single images of H&E-stained slides were acquired with a MicroPublisher 5.0 CCD camera (QImaging) on a Leica DMLB microscope equipped with 10× numerical aperture 0.25 and 40× numerical aperture 0.65 HC FL PLAN objectives.
Image analysis. For the analysis of MLCK1 or MLCK2 localization in cultured monolayers (Figs. 1d,e, 2g, and 3b) , the PAMR was defined using labeled phalloidin. ImageJ was used to generate a region of interest (ROI) around the entire cell (just outside the PAMR) and a separate intracellular ROI (just inside the PAMR). The total intensity of the area between the two ROIs was divided by the total intensity of the larger ROI to determine the fraction of MLCK at the PAMR. At least three independent monolayers (Transwells) were analyzed for each condition, with 3-5 fields measured in each monolayer. Each point represents the mean values from cells in one microscope field; n represents the number of fields analyzed.
For the analysis of MLCK1 localization in intestinal tissues (Fig. 4e,j) , phalloidin staining was used to define a ROI at the PAMR as well as a larger ROI encompassing the entire cell. Each ROI included a segment of 5-10 epithelial cells (approximately 100 μm). The fraction of PAMR-associated MLCK was determined from the two ROIs as for the monolayers. Each point represents a mean of 3-5 fields measured in a single tissue specimen; n represents the number of independent biopsy fragments or mice analyzed for human or mouse tissues, respectively. MLC phosphorylation was quantified using MetaMorph version 7. The counting of EdU-labeled nuclei and CD3 + T cells was performed manually.
In vitro kinase assay. Confluent Caco-2 BBe monolayers expressing MLCK1 and MLCK2 were used as the source of MLC kinase. After dilution in kinase reaction buffer (20 mM 3-morpholinopropane-1-sulfonic acid, pH 7.4, 2 mM MgCl 2 , 0.25 mM CaCl 2 , and 0.2 μM calmodulin), small molecule inhibitor compounds obtained from the NCI or PIK were added to the reactions, as indicated. The reaction was initiated by the addition of γ 32 P-ATP (ICN) and 5 μM recombinant MLC 12 and transferring to 30 °C. MLC phosphorylation was determined by autoradiography after SDS-PAGE. All experiments were performed at least three times, with triplicate or greater samples in each experiment.
Gel contraction assay. Human aortic smooth muscle cells (Invitrogen) were maintained in Medium 231 supplemented with smooth muscle growth supplement. Collagen lattices were prepared by mixing, on ice, collagen I (2 mg ml −1 ) in 0.1% acetic acid with supplemented Medium 231 and 0.1 N NaOH to neutralize the pH before adding a cell suspension, as described 55, 56 . After polymerization (30 min at 37 °C), gels were detached and covered with supplemented Medium 231, with or without small molecule inhibitor compounds obtained from the NCI as indicated. After 24 h, lattices were photographed and the percentage gel contraction was calculated using ImageJ. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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